- Research works
- 111 ▲ 234% vs 2013–17
- Citations
- 1.9k 17.1 per fractional work
- Top-10% rate
- 17.4% record average 16.5%
- Open access
- 54% world 28%
Not ranked overall: Rohto Pharmaceutical (Japan) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Pharmacology, Toxicology and Pharmaceutics, 9.9×. Every wedge is a field page.
- Pharmacology, Toxicology and Pharmaceutics 9.9×
- Immunology and Microbiology 8.9×
- Veterinary 4.4×
- Neuroscience 3.4×
- Biochemistry, Genetics and Molecular Biology 3.3×
- Chemistry 3.0×
- Medicine 2.0×
- Nursing 1.8×
- Agricultural and Biological Sciences 1.3×
- Physics and Astronomy 1.3×
- Dentistry 0.8×
- Engineering 0.4×
- Health Professions 0.4×
- Materials Science 0.3×
- Environmental Science 0.2×
- Psychology 0.1×
- Computer Science 0.0×
Who are the top researchers at Rohto Pharmaceutical (Japan)?
Ranked on the composite score, Toru Okubo lead among researchers whose main affiliation is Rohto Pharmaceutical (Japan).
- 1 Toru Okubo Japan · #1,619,709 worldwide 8 citations · 17 works
Which keywords describe research at Rohto Pharmaceutical (Japan)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Inflammation, Cancer, Epidemiology, Regeneration, Autoimmunity, Immunity, Antioxidant and Cardiovascular Disease.
- Regeneration
- Autoimmunity
- Cardiovascular Disease
- Epidemiology
- Inflammation
- Cancer
- Antioxidant
- Oxidative Stress
- Immunity
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 9 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 9 words, with their numbers
- Inflammation4▲ 6.3×20 topics
- Epidemiology3▲ 2.7×14 topics
- Cancer2▲ 6.2×16 topics
- Cardiovascular Disease1▲ 3.8×7 topics
- Antioxidant1▲ 5.6×7 topics
- Autoimmunity1▲ 27×3 topics
- Oxidative Stress1▲ 2.4×8 topics
- Regeneration1▲ 21×3 topics
- Immunity1▲ 8.8×5 topics
Which research topics does Rohto Pharmaceutical (Japan) publish most on?
By volume in 2022–2025: NMR spectroscopy and applications, T-cell and B-cell Immunology, Ocular Surface and Contact Lens and Corneal Surgery and Treatments.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 NMR spectroscopy and applications Nuclear and High Energy Physics 1 works
- 2 T-cell and B-cell Immunology Immunology 1 works
- 3 Ocular Surface and Contact Lens Public Health, Environmental and Occupational Health 1 works
- 4 Corneal Surgery and Treatments Radiology, Nuclear Medicine and Imaging 1 works
- 5 Mesenchymal stem cell research Genetics 1 works
- 6 Dermatology and Skin Diseases Dermatology 1 works
- 7 Glaucoma and retinal disorders Ophthalmology 0 works
- 8 Immunotherapy and Immune Responses Immunology 0 works
- 9 melanin and skin pigmentation Cell Biology 0 works
- 10 Spectroscopy and Chemometric Analyses Analytical Chemistry 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Rohto Pharmaceutical (Japan)'s research output changed?
Output in 2018–2022 was 234% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Osaka
- The University of Osaka
- Osaka City University
- Kindai University
- National Cerebral and Cardiovascular Center
- Kansai Medical University
- Takeda (Japan)
- Osaka International Cancer Institute
- Osaka Institute of Technology
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.